Agile Therapeutics (NASDAQ:AGRX) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report issued on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reiterated a “hold” rating on shares of Agile Therapeutics in a report on Monday, March 18th.

Agile Therapeutics Stock Performance

AGRX opened at $0.40 on Friday. The business’s 50 day moving average price is $0.56 and its 200 day moving average price is $1.38. The stock has a market capitalization of $2.74 million, a PE ratio of -0.04 and a beta of 1.42. Agile Therapeutics has a one year low of $0.20 and a one year high of $6.97.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Thursday, March 28th. The specialty pharmaceutical company reported ($1.46) EPS for the quarter. The firm had revenue of $3.62 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC raised its stake in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,000 shares during the period. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.